Alcon Partners with RxSight to Develop Adjustable PCIOLs

Shots: Alcon has entered into a non-exclusive collaboration with RxSight to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) Under the collaboration, RxSight & Alcon will combine RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to co-develop adjustable PCIOLs for optimized cataract surgery outcomes As per the deal, RxSight will lead development & manufacturing, receiving…

ByRidhi RastogiJuly 7, 2026

NEWS

Natera Reports Publication of Signatera MRD Test Results for Resected Metastatic Colorectal Cancer in JAMA Oncology

Shots: Natera has reported the publication of data on Signatera, a personalized MRD test for resected colorectal liver metastases (CRLM), in JAMA Oncology, with findings also presented at the ESMO GI 2026 The analysis incl. 298 pts from the GALAXY trial, an observational arm of CIRCULATE-Japan, assessing outcomes by MRD status & adj. CT (ACT) use…

ByRidhi RastogiJuly 6, 2026

NEWS

Visby Medical Secures FDA Clearance for At-Home Flu & COVID-19 PCR Test

Shots: The US FDA has granted clearance to Flu and COVID-19 Test, an at-home PCR test capable of detecting multiple respiratory viruses, expanding its portfolio of over-the-counter molecular diagnostics The test delivers PCR-quality results in 30min. & detects COVID-19 and influenza A/B at home, enabling earlier diagnosis & timely treatment decisions, incl. access to antiviral…

ByRidhi RastogiJuly 3, 2026

NEWS

Median Technologies Receives CE Mark for eyonis LCS to Detect and Diagnose Lung Cancer

Shots: Median Technologies has received CE Mark for eyonis Lung Cancer Screening (LCS) to detect & diagnose lung cancer In testing eyonis LCS has showed 93.3% sensitivity & 92.4% specificity, with 68% reduction of False Positives & 66% reduction of False Negatives, minimizing unnecessary follow-ups eyonis Lung Cancer Screening is an AI-powered computer-aided detection & diagnosis…

ByRidhi RastogiJuly 3, 2026

NEWS

RefleXion Seeks FDA Clearance for Anchor Point Tumor Tracking

Shots: The US FDA has received a 510(k) premarket notification for Anchor Point Tracking, a tumor tracking technology designed for use with its new RefleXion X2 radiotherapy platform Filing is backed by extensive system validation & phantom testing, with additional data from academic investigators demonstrating improved target tracking, dose conformity, motion management, & organ-at-risk sparing…

ByRidhi RastogiJuly 1, 2026

NEWS

Novocure Receives the CE Mark for Optune Pax with CT for Pancreatic Cancer

Shots: CE Mark was based on the P-III (PANOVA-3) trial assessing Optune Pax used concomitantly with gem/nab-pac (n=285), vs CT alone (n=286) in 571 adults with locally advanced pancreatic cancer, with launch expected in Germany in coming wks. Trial improved mOS to 16.2 vs 14.2mos. in ITT, with 1yr. survival of 68.1% vs 60.2%. In…

ByRidhi RastogiJuly 1, 2026

NEWS

Spotlight Medical Gains CE Mark for myStage Dx as an AI-Based Prognostic Test for ER+/HER2- Early Breast Cancer

Shots: Spotlight Medical has received CE marking under the EU IVDR for myStage Dx, an AI-enabled prognostic test designed to support risk stratification in patients with ER+/HER2- early breast cancer Test analyzes digitized H&E-stained FFPE pathology slides alongside routine clinicopathological variables to generate a binary prognostic classification of Low Risk or Not Low Risk In…

ByRidhi RastogiJune 24, 2026

EVENTS

HLTH Europe 2026: Key Highlights & Industry Insights

Shots • HLTH Europe 2026 brought together over 5,000 healthcare leaders, investors, policymakers, payers, providers, pharmaceutical executives, and digital health innovators in Amsterdam to explore the future of healthcare innovation. • Healthcare has a paradox: brilliant point solutions are failing not because they don't work, but because they can't talk to each other. A patient…

ByAditya SinghJune 22, 2026

NEWS

FiberSense Receives CE Mark for its Continuous Glucose Monitoring (CGM) System

Shots: FiberSense has received the CE Marking for its CGM System as a Class IIb medical device, with the company planning to launch in select markets, with initial orders confirmed & first deliveries expected in late 2026 The company is preparing manufacturing scale-up, logistics, customer support, & market access activities for launch, while advancing its…

ByRidhi RastogiJune 17, 2026

NEWS

SurGenTec Wins the US FDA Clearance for ION-L to Treat Degenerative Disc Disease

Shots: The US FDA has granted clearance to SurGenTec's ION-L Lumbar Facet Fixation System for the treatment of skeletally mature pts with degenerative disc disease (DDD) from L3 to S1 who have failed conservative care Clearance is supported by a multicenter, IRB-approved clinical study in a high-risk, real-world patient population, with independent radiographic reviews confirming…

ByRidhi RastogiJune 16, 2026

Alcon Partners with RxSight to Develop Adjustable PCIOLs

Natera Reports Publication of Signatera MRD Test Results for Resected Metastatic Colorectal Cancer in JAMA Oncology

Visby Medical Secures FDA Clearance for At-Home Flu & COVID-19 PCR Test

Median Technologies Receives CE Mark for eyonis LCS to Detect and Diagnose Lung Cancer

RefleXion Seeks FDA Clearance for Anchor Point Tumor Tracking

Novocure Receives the CE Mark for Optune Pax with CT for Pancreatic Cancer

Spotlight Medical Gains CE Mark for myStage Dx as an AI-Based Prognostic Test for ER+/HER2- Early Breast Cancer

HLTH Europe 2026: Key Highlights & Industry Insights

FiberSense Receives CE Mark for its Continuous Glucose Monitoring (CGM) System

SurGenTec Wins the US FDA Clearance for ION-L to Treat Degenerative Disc Disease

Contact US

FOLLOW US